Oncogene Inhibitor Global Market Report 2025

Description

An oncogene inhibitor is a type of therapeutic agent or drug developed to inhibit the function of oncogenes, which are genes capable of triggering cancer when they become overactive or mutated. These inhibitors specifically target the abnormal proteins that oncogenes produce, which are responsible for driving unregulated cell division and tumor growth. By impeding these proteins, oncogene inhibitors can help to reduce or halt the development of certain cancers.

Oncogene inhibitors are mainly available in two forms: oral and injectable. Oral medications are taken by mouth and typically come in forms such as pills, tablets, capsules, or liquid solutions. These are used across various drug categories, including biologics, small molecule drugs, and combination therapies. The key indications include breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and others. These drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and they are utilized by different end users such as hospitals, specialty clinics, and other healthcare facilities.

The oncogene inhibitor market research report is one of a series of new reports from The Business Research Company that provides oncogene inhibitor market statistics, including oncogene inhibitor industry global market size, regional shares, competitors with an oncogene inhibitor market share, oncogene inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the oncogene inhibitor industry. This oncogene inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncogene inhibitor market size has grown strongly in recent years. It will grow from $39.68 billion in 2024 to $43.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period is due to factors such as increased research on resistance mechanisms, the expansion of targeted therapies, heightened research efforts for lung cancer treatment, rising investment in KRAS and MYC inhibitors, and boosted funding and grants.

The oncogene inhibitor market size is expected to see strong growth in the next few years. It will grow to $60.36 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is due to increased healthcare investments, the emphasis on tumor-agnostic treatments, rising use of targeted therapies, supportive regulatory and reimbursement frameworks, and the advancement of personalized medicine and companion diagnostics. Key trends expected during this period include the emergence of next-generation KRAS inhibitors, AI-powered drug discovery platforms, integration of real-time liquid biopsy, modulation of the tumor microenvironment, and the development of targeted nanoparticle-based drug delivery systems.

An increase in the prevalence of cancer is expected to propel the growth of the oncogene inhibitor market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. It is increasing due to unhealthy lifestyles, as habits such as smoking, poor diet, lack of exercise, and alcohol use weaken the body and promote the growth of cancerous cells. Oncogene inhibitors help combat cancer by targeting and blocking specific genes that drive cancer cell growth, thereby slowing or stopping tumor development and progression. For instance, in July 2024, according to a report published by Cancer Research UK, a UK-based charity, the average annual number of new melanoma skin cancer cases in the UK is expected to increase from approximately 20,800 in 2023-2025 to around 26,500 in 2038-2040. Therefore, an increase in the prevalence of cancer is driving the growth of the oncogene inhibitor market.

Major companies operating in the oncogene inhibitor market are focusing on developing innovative treatment options, such as novel functional genomic approaches, to enhance the precision and efficacy of cancer treatments. Novel functional genomic approaches refer to advanced methodologies that integrate various genomic, transcriptomic, and epigenomic data to understand gene functions and their roles in diseases such as cancer. For instance, in May 2024, Delphia Therapeutics, a US-based biotechnology company, introduced a novel approach called activation lethality to exploit cancer's vulnerability to oncogene overactivation. Leading oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this strategy. Activation lethality targets the excessive activation of oncogenes, genes that, when mutated or highly expressed, can drive cancer development. Some cancer cells rely on this overactivation for survival, and by inducing lethal stress through targeted intervention, this approach selectively kills those cancer cells while sparing healthy ones.

In November 2023, Revolution Medicines Inc., a US-based biotech company, acquired EQRx for an undisclosed amount. Through this acquisition, EQRx benefits by aligning with a company that has a strong focus on developing RAS(ON) inhibitor drugs for RAS-driven cancers, potentially accelerating the development and commercialization of its oncology programs. Additionally, the acquisition offers EQRx greater access to resources, expertise, and infrastructure, enhancing its ability to advance innovative oncogene inhibitor therapies. EQRx Inc. is a US-based biotech company that offers oncogene inhibitors.

Major players in the oncogene inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncogene inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncogene inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncogene inhibitor market consists of sales of imatinib, erlotinib, gefitinib, vemurafenib, dabrafenib, crizotinib, and ceritinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncogene Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncogene inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncogene inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncogene inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Oral; Injection
2) By Drug Class: Small Molecule Drugs; Biologics; Combination Therapies
3) By Indication: Breast Cancer; Ovarian Cancer; Lung Cancer; Pancreas Cancer; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors; Targeted Therapy Pills; Tyrosine Kinase Inhibitors (TKIs)
2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs); Peptide Receptor Radioligand Therapy (PRRT); Small Molecule Inhibitors (Injectable); Gene Therapy Injections
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r36003

1. Executive Summary

2. Oncogene Inhibitor Market Characteristics

3. Oncogene Inhibitor Market Trends And Strategies

4. Oncogene Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oncogene Inhibitor Growth Analysis And Strategic Analysis Framework

5.1. Global Oncogene Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oncogene Inhibitor Market Growth Rate Analysis
5.4. Global Oncogene Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oncogene Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oncogene Inhibitor Total Addressable Market (TAM)

6. Oncogene Inhibitor Market Segmentation

6.1. Global Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injection
6.2. Global Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Drugs
Biologics
Combination Therapies
6.3. Global Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Ovarian Cancer
Lung Cancer
Pancreas Cancer
Other Indications
6.4. Global Oncogene Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Oncogene Inhibitor Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.6. Global Oncogene Inhibitor Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Inhibitors
Targeted Therapy Pills
Tyrosine Kinase Inhibitors (TKIs)
6.7. Global Oncogene Inhibitor Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies (MAbs)
Peptide Receptor Radioligand Therapy (PRRT)
Small Molecule Inhibitors (Injectable)
Gene Therapy Injections

7. Oncogene Inhibitor Market Regional And Country Analysis

7.1. Global Oncogene Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oncogene Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncogene Inhibitor Market

8.1. Asia-Pacific Oncogene Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncogene Inhibitor Market

9.1. China Oncogene Inhibitor Market Overview
9.2. China Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncogene Inhibitor Market

10.1. India Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncogene Inhibitor Market

11.1. Japan Oncogene Inhibitor Market Overview
11.2. Japan Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncogene Inhibitor Market

12.1. Australia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncogene Inhibitor Market

13.1. Indonesia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncogene Inhibitor Market

14.1. South Korea Oncogene Inhibitor Market Overview
14.2. South Korea Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncogene Inhibitor Market

15.1. Western Europe Oncogene Inhibitor Market Overview
15.2. Western Europe Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncogene Inhibitor Market

16.1. UK Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncogene Inhibitor Market

17.1. Germany Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncogene Inhibitor Market

18.1. France Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncogene Inhibitor Market

19.1. Italy Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncogene Inhibitor Market

20.1. Spain Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncogene Inhibitor Market

21.1. Eastern Europe Oncogene Inhibitor Market Overview
21.2. Eastern Europe Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncogene Inhibitor Market

22.1. Russia Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncogene Inhibitor Market

23.1. North America Oncogene Inhibitor Market Overview
23.2. North America Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncogene Inhibitor Market

24.1. USA Oncogene Inhibitor Market Overview
24.2. USA Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncogene Inhibitor Market

25.1. Canada Oncogene Inhibitor Market Overview
25.2. Canada Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncogene Inhibitor Market

26.1. South America Oncogene Inhibitor Market Overview
26.2. South America Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncogene Inhibitor Market

27.1. Brazil Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncogene Inhibitor Market

28.1. Middle East Oncogene Inhibitor Market Overview
28.2. Middle East Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncogene Inhibitor Market

29.1. Africa Oncogene Inhibitor Market Overview
29.2. Africa Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncogene Inhibitor Market Competitive Landscape And Company Profiles

30.1. Oncogene Inhibitor Market Competitive Landscape
30.2. Oncogene Inhibitor Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Oncogene Inhibitor Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Bristol-Myers Squibb Company
31.3. Novartis AG
31.4. GlaxoSmithKline plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Mirati Therapeutics Inc.
31.8. AstraZeneca PLC
31.9. Incyte Corporation
31.10. Blueprint Medicines Corporation
31.11. Astex Pharmaceuticals Inc.
31.12. G1 Therapeutics Inc.
31.13. Nurix Therapeutics Inc.
31.14. GenFleet Therapeutics Co Ltd.
31.15. Relay Therapeutics Inc.

32. Global Oncogene Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncogene Inhibitor Market

34. Recent Developments In The Oncogene Inhibitor Market

35. Oncogene Inhibitor Market High Potential Countries, Segments and Strategies

35.1 Oncogene Inhibitor Market In 2029 - Countries Offering Most New Opportunities
35.2 Oncogene Inhibitor Market In 2029 - Segments Offering Most New Opportunities
35.3 Oncogene Inhibitor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer